Form 4: Halozyme Therapeutics Director Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Jeffrey William Henderson, a director at Halozyme Therapeutics, sold shares of common stock on April 28, 2025, under a pre-arranged trading plan.
Summary
- On April 28, 2025, Jeffrey William Henderson, a director at Halozyme Therapeutics, sold 4,297 shares of common stock at a weighted average price of $60.337.
- An additional 200 shares were sold on the same day at a weighted average price of $60.995.
- These sales were executed under a written trading plan adopted on September 17, 2024, in accordance with Rule 10b5-1.
- Following these transactions, Henderson directly owns 28,611 shares of Halozyme Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock sales by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on inside information.
Stakeholder Impact
- The stock sale may have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2024-09-17 | Date of adoption of the Rule 10b5-1 written trading plan. |
| 2025-04-28 | Date of the reported stock sales. |
Keywords
Halozyme Therapeutics, Director Share Sale, Jeffrey William Henderson, Form 4, 10b5-1 Trading Plan, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.